NCT03247543View on ClinicalTrials.gov

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

October 17, 2018

Study Completion Date

October 17, 2018

Conditions
ADHD
Interventions
DRUG

Placebo

Placebo was administered once daily

DRUG

200mg SPN-812

200mg SPN-812 was administered once daily and compared to placebo

DRUG

400mg SPN-812

400mg SPN-812 was administered once daily and compared to placebo

Trial Locations (10)

29407

Carolina Clinical Trials, Inc., Charleston

32803

APG Research, LLC, Orlando

33319

Innovative Clinical Research, Inc, Lauderhill

33613

University of South Florida- Dept. of Psychiatry and Neurosciences, Tampa

66211

Psychiatric Associates, Overland Park

73118

Paradigm Research Professionals, Oklahoma City

77006

Bayou City Research Corporation, Houston

78759

BioBehavioral Research of Austin P.C., Austin

84015

Ericksen Research & Development, Clinton

90807

Alliance for Wellness, Long Beach

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT03247543 - Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD | Biotech Hunter | Biotech Hunter